#### COVID-19 vaccine brand unspecified analysis print

Á
All UK spontaneous reports received up to andÁncluding 11/08/21 for COVID-19 vaccines where theÁnrand has not been specified.

A CEÁ^][¦ơḥ -Ándh ˇ•]^&c^å ÁCHCÜÁ [Ác@ ÁŸ^||[ ÁÔæ å Á &@{ ^Áå[^•Á,[ơḥ^&^••æ á f Á, ^æ) Ác@æ Á f &æ Á &æ •^å Áà Ác@ Áçæ&&ð ^ÉĀ,}|^Ác@æ Áœ Á^][¦ơ¦Áœæ Áæ \*•] æðā;}Æā,æ Á @æç^EÁN}å^![ˆā \*Á;¦Á;¦^çā \*•|^Á &æ •^å Áà Âæç^EÁN}å^![ˆā \*Á;¦Á;¦^çā \*•|^Á ˇ}åãæť}[•^å Áā)}^\*,••Á}¦^|ææ^å Ái Áçæ&&ð æā j Ásæ Ææ [Æa^Áæð j á Áæ Áæ,][¦•EĂ @Á^|æãç^Á }
} ˇ{ à^¦Ææj å Á,æc ¦^Á, -Á^][¦•Æ Ø ¸ jå Ás@ ¦^-[¦^Á][oÁa^Á•^å Ái Ææ] ∫ æ ^Áæ Ææ ĉ Á -Ác@ Æåã-^!^}oÁ
çæ&&ð ^•ĒÁCHÁ^][¦•Ææ+Å^]oÁ;åå^¦Ææ] oð ¸æþÁ^çã ¸ÆþÁ;åå^¦Ái Åæ^}æâ Á,[••ãa|^Á,¸Áæ)•ĒÁ

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

Report Run Date: 02-Dec-2021

| Reaction Name                              | Total | Fatal |
|--|-------|-------|
| Blood disorders                            |       |       |
| Anaemia deficiencies                       |       |       |
| Iron deficiency anaemia                    | 1     | 0     |
| Anaemias NEC                               |       |       |
| Anaemia                                    | 3     | 0     |
| Anaemias haemolytic NEC                    |       |       |
| Haemolytic anaemia                         | 1     | 0     |
| Anaemias haemolytic immune                 |       |       |
| Autoimmune haemolytic anaemia              | 1     | 0     |
| Eosinophilic disorders                     |       |       |
| Eosinophilia                               | 1     | 0     |
| Haematological disorders                   |       |       |
| Blood disorder                             | 1     | 1     |
| Lymphatic system disorders NEC             |       |       |
| Lymph node pain                            | 4     | 0     |
| Lymphadenitis                              | 1     | 0     |
| Lymphadenopathy                            | 27    | 0     |
| Marrow depression and hypoplastic anaemias |       |       |
| Aplastic anaemia                           | 1     | 0     |
| Myelosuppression                           | 1     | 0     |
| Neutropenias                               |       |       |
| Neutropenia                                | 1     | 0     |
| Platelet disorders NEC                     |       |       |
| Platelet disorder                          | 1     | 0     |
| Thrombocytopenias                          |       |       |
| Immune thrombocytopenia                    | 4     | 3     |
| Thrombocytopenia                           | 9     | 0     |
| Blood disorders SOC TOTAL                  | 57    | 4     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

Report Run Date: 02-Dec-2021

| Reaction Name                              | Total | Fatal |
|--|-------|-------|
| Cardiac disorders                          |       |       |
| Cardiac conduction disorders               |       |       |
| Bundle branch block                        | 1     | 0     |
| Cardiac disorders NEC                      |       |       |
| Cardiac disorder                           | 1     | 0     |
| Cardiac signs and symptoms NEC             |       |       |
| Cardiac discomfort                         | 2     | 0     |
| Palpitations                               | 24    | 0     |
| Ischaemic coronary artery disorders        |       |       |
| Acute myocardial infarction                | 1     | 0     |
| Angina pectoris                            | 5     | 0     |
| Myocardial infarction                      | 9     | 3     |
| Myocardial disorders NEC                   |       |       |
| Left ventricular dysfunction               | 1     | 0     |
| Noninfectious myocarditis                  |       |       |
| Immune-mediated myocarditis                | 1     | 0     |
| Myocarditis                                | 1     | 0     |
| Noninfectious pericarditis                 |       |       |
| Pericarditis                               | 3     | 0     |
| Rate and rhythm disorders NEC              |       |       |
| Bradycardia                                | 1     | 0     |
| Cardiac flutter                            | 2     | 0     |
| Postural orthostatic tachycardia syndrome  | 1     | 0     |
| Tachycardia                                | 6     | 0     |
| Supraventricular arrhythmias               |       |       |
| Atrial fibrillation                        | 4     | 0     |
| Supraventricular tachycardia               | 1     | 0     |
| Ventricular arrhythmias and cardiac arrest |       |       |
| Cardiac arrest                             | 2     | 1     |
| Cardiac disorders SOC TOTAL                | 66    | 4     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

Report Run Date: 02-Dec-2021

| Reaction Name                    | Total | Fatal |
|----------------------------------|-------|-------|
| Congenital disorders             |       |       |
| Cardiac disorders congenital NEC |       |       |
| Heart disease congenital         | 1     | 0     |
| Congenital disorders SOC TOTAL   | 1     | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

Report Run Date: 02-Dec-2021

| Reaction Name                | Total | Fatal |
|------------------------------|-------|-------|
| Ear disorders                |       |       |
| Ear disorders NEC            |       |       |
| Ear discomfort               | 2     | 0     |
| Ear disorder                 | 1     | 0     |
| Ear pain                     | 5     | 0     |
| Ear swelling                 | 1     | 0     |
| Eustachian tube disorders    |       |       |
| Eustachian tube disorder     | 1     | 0     |
| Eustachian tube dysfunction  | 1     | 0     |
| External ear disorders NEC   |       |       |
| Excessive cerumen production | 2     | 0     |
| Hearing losses               |       |       |
| Deafness                     | 3     | 0     |
| Deafness unilateral          | 1     | 0     |
| Hypoacusis                   | 4     | 0     |
| Hyperacusia                  |       |       |
| Hyperacusis                  | 1     | 0     |
| Inner ear disorders NEC      |       |       |
| Vestibular disorder          | 1     | 0     |
| Inner ear signs and symptoms |       |       |
| Tinnitus                     | 20    | 0     |
| Vertigo                      | 11    | 0     |
| Ear disorders SOC TOTAL      | 54    | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

Report Run Date: 02-Dec-2021

| Reaction Name                     | Total | Fatal |
|-----------------------------------|-------|-------|
| Endocrine disorders               |       |       |
| Female gonadal function disorders |       |       |
| Ovulation delayed                 | 1     | 0     |
| Endocrine disorders SOC TOTAL     | 1     | 0     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

Report Run Date: 02-Dec-2021

| Reaction Name  | Total | Fatal |
|--|-------|-------|
| Eye disorders  |       |       |
| Choroid and vitreous structural change, deposit and degeneration |       |       |
| Vitreous floaters  | 5     | 0     |
| Corneal infections, oedemas and inflammations                    |       |       |
| Keratitis  | 1     | 0     |
| Iris and uveal tract infections, irritations and inflammations   |       |       |
| Iridocyclitis  | 1     | 0     |
| Lacrimation disorders  |       |       |
| Dry eye  | 2     | 0     |
| Lacrimation increased  | 2     | 0     |
| Lid, lash and lacrimal infections, irritations and inflammations |       |       |
| Chalazion  | 1     | 0     |
| Eyelid cyst  | 1     | 0     |
| Swelling of eyelid   | 1     | 0     |
| Ocular disorders NEC   |       |       |
| Eye disorder   | 2     | 0     |
| Eye pain   | 5     | 0     |
| Eye swelling   | 8     | 0     |
| Ocular discomfort  | 1     | 0     |
| Periorbital swelling   | 3     | 0     |
| Ocular infections, inflammations and associated manifestations   |       |       |
| Eye allergy  | 1     | 0     |
| Eye pruritus   | 3     | 0     |
| Ocular sensation disorders                                       |       |       |
| Photophobia  | 4     | 0     |
| Pupil disorders  |       |       |
| Pupil fixed  | 1     | 0     |
| Pupils unequal   | 1     | 0     |
| Retinal bleeding and vascular disorders (excl retinopathy)       |       |       |
| Retinal haemorrhage  | 1     | 0     |
| Retinal vein occlusion   | 2     | 0     |
| Retinal structural change, deposit and degeneration              |       |       |
| Macular degeneration   | 1     | 0     |
| Retinal toxicity   | 1     | 0     |
| Visual disorders NEC   |       |       |
| Diplopia   | 5     | 0     |
| Photopsia  | 2     | 0     |
| Vision blurred   | 10    | 0     |
| Visual impairment and blindness (excl colour blindness)          |       |       |
| Blindness  | 4     | 0     |
| Blindness transient  | 1     | 0     |
| Visual impairment  | 4     | 0     |
| Eve disorders SOC TOTAL  | 74    | 0     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1  Reaction Name                   | Total | Fatal |
|--|-------|-------|
| Gastrointestinal disorders                                   |       |       |
| Anal and rectal pains  |       |       |
| Proctalgia   | 1     | 0     |
| Colitis (excl infective)                                     |       |       |
| Colitis  | 2     | 0     |
| Colitis ulcerative   | 1     | 0     |
| Crohn's disease  | 1     | 0     |
| Dental pain and sensation disorders                          |       |       |
| Toothache  | 3     | 0     |
| Diarrhoea (excl infective)                                   |       |       |
| Diarrhoea  | 45    | 0     |
| Dyspeptic signs and symptoms                                 |       |       |
| Dyspepsia  | 3     | 0     |
| Faecal abnormalities NEC                                     |       |       |
| Abnormal faeces  | 2     | 0     |
| Faeces discoloured   | 3     | 0     |
| Flatulence, bloating and distension                          |       |       |
| Abdominal distension   | 4     | 0     |
| Flatulence   | 1     | 0     |
| Gastritis (excl infective)                                   |       |       |
| Gastritis  | 1     | 0     |
| Gastrointestinal and abdominal pains (excl oral and throat)  |       |       |
| Abdominal pain   | 10    | 0     |
| Abdominal pain lower   | 2     | 0     |
| Abdominal pain upper   | 24    | 0     |
| Abdominal tenderness   | 1     | 0     |
| Gastrointestinal pain  | 2     | 0     |
| Gastrointestinal atonic and hypomotility disorders NEC       |       |       |
| Constipation   | 3     | 0     |
| Gastrooesophageal reflux disease                             | 3     | 0     |
| Gastrointestinal signs and symptoms NEC                      |       |       |
| Abdominal discomfort   | 15    | 0     |
| Dysphagia  | 2     | 0     |
| Gastrointestinal spastic and hypermotility disorders         |       |       |
| Irritable bowel syndrome                                     | 2     | 0     |
| Gastrointestinal stenosis and obstruction NEC                |       |       |
| lleus  | 1     | 0     |
| Gastrointestinal vascular occlusion and infarction           |       |       |
| Mesenteric vein thrombosis                                   | 1     | 0     |
| Gingival disorders, signs and symptoms NEC                   |       |       |
| Gingival pain  | 2     | 0     |
| Haemorrhoids and gastrointestinal varices (excl oesophageal) |       |       |
| Haemorrhoids   | 1     | 0     |
| Intestinal haemorrhages                                      |       |       |
| Intestinal haemorrhage                                       | 1     | 0     |
| Nausea and vomiting symptoms                                 |       |       |
| Nausea   | 123   | 0     |
| Retching   | 2     | 0     |
| Vomiting   | 47    | 0     |
| Vomiting projectile  | 2     | 0     |
| Non-site specific gastrointestinal haemorrhages              |       |       |
| Gastrointestinal haemorrhage                                 | 1     | 1     |
| Haematemesis   | 1     | 0     |
| Oral dryness and saliva altered                              |       |       |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

Report Run Date: 02-Dec-2021

| Reaction Name   | Total | Fatal |
|---|-------|-------|
| Gastrointestinal disorders ointestinal disorders cont'd |       |       |
| Dry mouth   | 1     | 0     |
| Oral soft tissue disorders NEC                          |       |       |
| Oral papule   | 1     | 0     |
| Oral soft tissue signs and symptoms                     |       |       |
| Hypoaesthesia oral                                      | 1     | 0     |
| Lip exfoliation   | 1     | 0     |
| Oral pain   | 1     | 0     |
| Paraesthesia oral                                       | 1     | 0     |
| Oral soft tissue swelling and oedema                    |       |       |
| Lip swelling  | 7     | 0     |
| Stomatitis and ulceration                               |       |       |
| Mouth ulceration  | 3     | 0     |
| Tongue disorders  |       |       |
| Glossitis   | 1     | 0     |
| Tongue signs and symptoms                               |       |       |
| Glossodynia   | 1     | 0     |
| Swollen tongue  | 2     | 0     |
| Tongue discolouration                                   | 1     | 0     |
| Gastrointestinal disorders SOC TOTAL                    | 334   | 1     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1  Reaction Name  | Total       | Fatal |
|---|-------------|-------|
| General disorders                           |             |       |
| Administration site reactions NEC           |             |       |
| Administration site erythema                | 1           | 0     |
| Application and instillation site reactions |             |       |
| Application site swelling                   | 1           | 0     |
| Asthenic conditions                         |             |       |
| Asthenia                                    | 36          | 0     |
| Chronic fatigue syndrome                    | 1           | 0     |
| Fatigue                                     | 187         | 0     |
| Malaise                                     | 79          | 0     |
| Body temperature altered                    |             |       |
| Hyperthermia                                | 1           | 0     |
| Death and sudden death                      |             |       |
| Death                                       | 11          | 11    |
| Sudden death                                | 1           | 1     |
| Febrile disorders                           |             |       |
| Pyrexia                                     | 150         | 0     |
| Feelings and sensations NEC                 |             |       |
| Chills                                      | 99          | 0     |
| Feeling abnormal                            | 22          | 0     |
| Feeling cold                                | 21          | 0     |
| Feeling hot                                 | 13          | 0     |
| Feeling of body temperature change          | 9           | 0     |
| Sensation of foreign body                   | 1           | 0     |
| Thirst                                      | 4           | 0     |
| Gait disturbances                           |             |       |
| Gait disturbance                            | 6           | 0     |
| Gait inability                              | 2           | 0     |
| General signs and symptoms NEC              |             |       |
| Condition aggravated                        | 7           | 0     |
| Crying                                      | 1           | 0     |
| General physical health deterioration       | 3           | 0     |
| Illness                                     | 27          | 0     |
| Influenza like illness                      | 32          | 0     |
| Local reaction                              | 1           | 0     |
| Peripheral swelling                         | 34          | 0     |
| Secretion discharge                         | 1           | 0     |
| Swelling                                    | 22          | 0     |
| Swelling face                               | 11          | 0     |
| Symptom recurrence                          | 1           | 0     |
| Unevaluable event                           | 1           | 0     |
| Inflammations                               |             |       |
| Inflammation                                | 6           | 0     |
| Systemic inflammatory response syndrome     | 1           | 0     |
| Injection site reactions                    |             |       |
| Injection site discomfort                   | 1           | 0     |
| Injection site erythema                     |             | 0     |
| Injection site inflammation                 | 2           | 0     |
| Injection site mass                         | 3<br>2<br>5 | 0     |
| Injection site pain                         | 11          | 0     |
| Injection site pruritus                     | 1           | 0     |
| Injection site swelling                     |             | 0     |
| Injection site warmth                       | 3           | 0     |
| Interactions                                |             |       |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                              | Total | Fatal |
|--|-------|-------|
| General disorders General disorders cont'd |       |       |
| Drug interaction                           | 1     | 0     |
| Mass conditions NEC                        |       |       |
| Cyst                                       | 2     | 0     |
| Nodule                                     | 1     | 0     |
| Oedema NEC                                 |       |       |
| Oedema peripheral                          | 1     | 0     |
| Pain and discomfort NEC                    |       |       |
| Axillary pain                              | 9     | 0     |
| Chest discomfort                           | 7     | 0     |
| Chest pain                                 | 27    | 0     |
| Discomfort                                 | 6     | 0     |
| Facial discomfort                          | 1     | 0     |
| Facial pain                                | 3     | 0     |
| Pain                                       | 76    | 0     |
| Tenderness                                 | 1     | 0     |
| Therapeutic and nontherapeutic responses   |       |       |
| Adverse drug reaction                      | 4     | 0     |
| Drug ineffective                           | 3     | 0     |
| Drug intolerance                           | 1     | 0     |
| No reaction on previous exposure to drug   | 1     | 0     |
| Surgical failure                           | 1     | 0     |
| Therapeutic product effect decreased       | 1     | 0     |
| Therapeutic product ineffective            | 1     | 0     |
| Therapeutic response decreased             | 1     | 0     |
| Therapeutic response unexpected            | 1     | 0     |
| Vaccination site reactions                 |       |       |
| Vaccination site bruising                  | 1     | 0     |
| Vaccination site erythema                  | 16    | 0     |
| Vaccination site hypoaesthesia             | 1     | 0     |
| Vaccination site induration                | 2     | 0     |
| Vaccination site inflammation              | 2 2   | 0     |
| Vaccination site mass                      | 4     | 0     |
| Vaccination site movement impairment       | 1     | 0     |
| Vaccination site pain                      | 12    | 0     |
| Vaccination site papule                    | 1     | 0     |
| Vaccination site pruritus                  | 3     | 0     |
| Vaccination site rash                      | 2     | 0     |
| Vaccination site reaction                  | 1     | 0     |
| Vaccination site scab                      | 1     | 0     |
| Vaccination site swelling                  | 9     | 0     |
| Vaccination site warmth                    | 5     | 0     |
| General disorders SOC TOTAL                | 1030  | 12    |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                    | Total | Fatal |
|----------------------------------|-------|-------|
| Hepatic disorders                |       |       |
| Cholecystitis and cholelithiasis |       |       |
| Cholecystitis acute              | 1     | 0     |
| Cholestasis and jaundice         |       |       |
| Jaundice                         | 1     | 0     |
| Hepatic vascular disorders       |       |       |
| Portal vein thrombosis           | 3     | 0     |
| Hepatic disorders SOC TOTAL      | 5     | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name   | Total | Fatal |
|---|-------|-------|
| Immune system disorders                                       |       |       |
| Acute and chronic sarcoidosis                                 |       |       |
| Sarcoidosis   | 1     | 0     |
| Allergic conditions NEC                                       |       |       |
| Hypersensitivity  | 5     | 0     |
| Allergies to foods, food additives, drugs and other chemicals |       |       |
| Allergy to vaccine  | 3     | 0     |
| Drug hypersensitivity   | 2     | 0     |
| Food allergy  | 1     | 0     |
| Anaphylactic and anaphylactoid responses                      |       |       |
| Anaphylactic reaction   | 2     | 0     |
| Atopic disorders  |       |       |
| Seasonal allergy  | 1     | 0     |
| Immune and associated conditions NEC                          |       |       |
| Bacille Calmette-Guerin scar reactivation                     | 1     | 0     |
| Immunodeficiency disorders NEC                                |       |       |
| Immunodeficiency  | 1     | 0     |
| Transplant rejections   |       |       |
| Corneal graft rejection                                       | 1     | 0     |
| Immune system disorders SOC TOTAL                             | 18    | 0     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1  Reaction Name      | Total | Fatal |
|---|-------|-------|
| Infections                                      |       |       |
| Abdominal and gastrointestinal infections       |       |       |
| Appendicitis                                    | 1     | 0     |
| Bacterial infections NEC                        |       |       |
| Arthritis bacterial                             | 1     | 0     |
| Breast infections                               |       |       |
| Mastitis  | 1     | 0     |
| Caliciviral infections                          |       |       |
| Norovirus infection                             | 1     | 0     |
| Central nervous system and spinal infections    |       |       |
| Encephalitis                                    | 1     | 0     |
| Meningitis aseptic                              | 1     | 0     |
| Clostridia infections                           |       | J     |
| Clostridium difficile infection                 | 1     | 0     |
| Coronavirus infections                          |       | J     |
| COVID-19  | 20    | 0     |
| Suspected COVID-19                              | 1     | 0     |
| Eye and eyelid infections                       |       |       |
| Eye infection                                   | 1     | 0     |
| Hordeolum                                       | 1     | 0     |
| Fungal infections NEC                           | ,     | Ŭ     |
| Fungal infection                                | 1     | 0     |
| Herpes viral infections                         | ,     |       |
| Genital herpes                                  | 2     | 0     |
| Herpes zoster                                   | 14    |       |
| Oral herpes                                     | 4     | 0     |
| Infections NEC                                  | 7     |       |
| Infection                                       | 6     | 0     |
| Localised infection                             | 1     | 0     |
| Infectious transmissions                        |       |       |
| Vaccine virus shedding                          | 1     | 0     |
| Influenza viral infections                      |       |       |
| Influenza                                       | 18    | 0     |
| Lower respiratory tract and lung infections     |       |       |
| Lower respiratory tract infection               | 3     | 1     |
| Pneumonia                                       | 9     |       |
| Mumps viral infections                          |       | _     |
| Mumps   | 1     | 0     |
| Sepsis, bacteraemia, viraemia and fungaemia NEC |       |       |
| Sepsis  | 2     | 0     |
| Skin structures and soft tissue infections      |       |       |
| Rash pustular                                   | 1     | 0     |
| Staphylococcal infections                       |       |       |
| Furuncle  | 1     | 0     |
| Trypanosomal infections                         |       |       |
| African trypanosomiasis                         | 1     | 0     |
| Upper respiratory tract infections              |       |       |
| Laryngitis                                      | 1     | 0     |
| Nasopharyngitis                                 | 8     | 0     |
| Sinusitis                                       | 1     | 0     |
| Tonsillitis                                     | 2     | 0     |
| Urinary tract infections                        |       |       |
| Kidney infection                                | 2     | 0     |
| Urinary tract infection                         | 4     |       |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                | Total | Fatal |
|------------------------------|-------|-------|
| Infections Infections cont'd |       |       |
| Viral infections NEC         |       |       |
| Gastroenteritis viral        | 1     | 0     |
| Sweating fever               | 1     | 0     |
| Viral infection              | 2     | 0     |
| Infections SOC TOTAL         | 117   | 4     |

### Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1                                 |               |              |  |
|---|---------------|--------------|--|
| Reaction Name   | <u> Total</u> | <u>Fatal</u> |  |
| njuries   |               |              |  |
| Bone and joint injuries NEC                                 |               |              |  |
| Joint injury  | 1             | (            |  |
| Cerebral injuries NEC                                       |               |              |  |
| Subdural haematoma  | 1             | 1            |  |
| Exposures associated with pregnancy, delivery and lactation |               |              |  |
| Maternal exposure during breast feeding                     | 1             | (            |  |
| Maternal exposure during pregnancy                          | 4             | (            |  |
| Exposures to agents or circumstances NEC                    |               |              |  |
| Exposure to vaccinated person                               | 2             | (            |  |
| Eye injuries NEC  |               |              |  |
| Eye contusion   | 1             | (            |  |
| Eye injury  | 3             | (            |  |
| Intentional product misuses                                 |               |              |  |
| Intentional product misuse                                  | 2             | (            |  |
| Intentional product use issues                              |               |              |  |
| Intentional dose omission                                   | 2             |              |  |
| Medication errors, product use errors and issues NEC        |               |              |  |
| Medication error  | 1             |              |  |
| Prescription drug used without a prescription               | 1             | (            |  |
| Vaccination error   | 1             |              |  |
| Wrong technique in product usage process                    | 2             | (            |  |
| Muscle, tendon and ligament injuries                        |               |              |  |
| Muscle strain   | 1             | (            |  |
| Tendon rupture  | 1             | (            |  |
| Nerve injuries NEC  |               |              |  |
| Nerve injury  | 1             | (            |  |
| Non-site specific injuries NEC                              |               |              |  |
| Fall  | 10            | (            |  |
| Non-site specific procedural complications                  |               |              |  |
| Incision site pain  | 1             | (            |  |
| Injection related reaction                                  | 2             | (            |  |
| Off label uses  |               |              |  |
| Off label use   | 1             | (            |  |
| Overdoses NEC   |               |              |  |
| Overdose  | 1             | (            |  |
| Product administration errors and issues                    |               |              |  |
| Expired product administered                                | 1             | (            |  |
| Inappropriate schedule of product administration            | 1             |              |  |
| Incorrect route of product administration                   | 1             | (            |  |
| Product administered at inappropriate site                  | 1             | (            |  |
| Product dose omission in error                              | 1             |              |  |
| Product dose omission issue                                 | 2             | (            |  |
| Wrong product administered                                  | 1             |              |  |
| Product dispensing errors and issues                        |               |              |  |
| Product dispensing error                                    | 1             |              |  |
| Site specific injuries NEC                                  |               |              |  |
| Limb injury   | 1             |              |  |
| Spinal column injury  | 1             |              |  |
| Skin injuries NEC   |               |              |  |
| Contusion   | 13            | (            |  |
| Thermal burns   |               |              |  |
| Burns third degree  | 1             | (            |  |
| Underdoses NEC  |               |              |  |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                     | Total | Fatal |
|-----------------------------------|-------|-------|
| Injuries Injuries cont'd          |       |       |
| Prescribed underdose              | 1     | 0     |
| Vaccination related complications |       |       |
| Vaccination complication          | 10    | 0     |
| Injuries SOC TOTAL                | 76    | 1     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name   | Total | Fatal |
|---|-------|-------|
| Investigations  |       |       |
| Blood gas and acid base analyses  |       |       |
| Oxygen saturation decreased   | 1     | 0     |
| Carbohydrate tolerance analyses (incl diabetes)   |       |       |
| Blood glucose increased   | 2     | 0     |
| Cardiac auscultatory investigations   |       |       |
| Cardiac murmur  | 2     | 0     |
| Cardiac function diagnostic procedures  |       |       |
| Myocardial strain imaging   | 1     | 0     |
| Cerebrospinal fluid tests (excl microbiology)   |       |       |
| CSF glucose decreased   | 1     | 0     |
| CSF protein increased   | 1     | 0     |
| Cholesterol analyses  |       |       |
| Blood cholesterol increased   | 1     | 0     |
| Coagulation and bleeding analyses   |       |       |
| Fibrin D dimer increased  | 2     | 0     |
| International normalised ratio increased  | 3     | 0     |
| Heart rate and pulse investigations   |       |       |
| Heart rate  | 7     | 0     |
| Heart rate decreased  | 1     | 0     |
| Heart rate increased  | 5     | 0     |
| Heart rate irregular  | 1     | 0     |
| Immunology skin tests NEC   |       |       |
| Skin test positive  | 1     | 0     |
| Investigations NEC  |       |       |
| Blood test  | 1     | 0     |
| Quality of life decreased   | 1     | 0     |
| Liver function analyses   |       |       |
| Liver function test   | 1     | 0     |
| Mineral and electrolyte analyses  |       |       |
| Blood iron decreased  | 1     | 0     |
| Blood potassium decreased   | 1     | 0     |
| Physical examination procedures and organ system status                                       |       |       |
| Body temperature  | 2     | 0     |
| Body temperature abnormal   | 1     | 0     |
| Body temperature decreased  | 2     | 0     |
| Body temperature fluctuation  | 1     | 0     |
| Body temperature increased  | 4     | 0     |
| Respiratory rate increased  | 1     | 0     |
| Weight decreased  | 5     | 0     |
| Weight increased  | 1     | 0     |
| Platelet analyses   |       |       |
| Platelet count decreased  | 1     | 0     |
| Red blood cell analyses   |       |       |
| Haemoglobin E   | 1     | 0     |
| Haemoglobin decreased   | 1     | 0     |
| Respiratory and pulmonary function diagnostic procedures  Peak expiratory flow rate decreased | 1     | 0     |
| Skeletal and cardiac muscle analyses  |       |       |
| Blood creatine phosphokinase increased  | 1     | 0     |
| Therapeutic drug monitoring analyses  |       |       |
| Anticoagulation drug level below therapeutic  | 1     | 0     |
| Triglyceride analyses   |       |       |
| Blood triglycerides   | 1     | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                            | Total | Fatal |
|--|-------|-------|
| Investigations Investigations cont'd     |       |       |
| Blood triglycerides increased            | 1     | 0     |
| Vascular tests NEC (incl blood pressure) |       |       |
| Blood pressure decreased                 | 1     | 0     |
| Blood pressure increased                 | 8     | 0     |
| Virus identification and serology        |       |       |
| SARS-CoV-2 test                          | 1     | 0     |
| SARS-CoV-2 test false negative           | 1     | 0     |
| SARS-CoV-2 test negative                 | 2     | 0     |
| SARS-CoV-2 test positive                 | 2     | 0     |
| White blood cell analyses                |       |       |
| Neutrophil count decreased               | 3     | 0     |
| Investigations SOC TOTAL                 | 77    | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                        | Total | Fatal |
|--------------------------------------|-------|-------|
| Metabolic disorders                  |       |       |
| Appetite disorders                   |       |       |
| Decreased appetite                   | 37    | 0     |
| Hypophagia                           | 2     | 0     |
| Increased appetite                   | 1     | 0     |
| Diabetes mellitus (incl subtypes)    |       |       |
| Diabetes mellitus                    | 1     | 0     |
| Diabetes mellitus inadequate control | 1     | 0     |
| Disorders of purine metabolism       |       |       |
| Gout                                 | 4     | 0     |
| Electrolyte imbalance NEC            |       |       |
| Electrolyte imbalance                | 1     | 0     |
| Hyperglycaemic conditions NEC        |       |       |
| Hyperglycaemia                       | 2     | 0     |
| Phosphorus metabolism disorders      |       |       |
| Hypophosphataemia                    | 1     | 0     |
| Sodium imbalance                     |       |       |
| Hyponatraemia                        | 1     | 0     |
| Total fluid volume decreased         |       |       |
| Dehydration                          | 4     | 0     |
| Water soluble vitamin deficiencies   |       |       |
| Folate deficiency                    | 1     | 0     |
| Metabolic disorders SOC TOTAL        | 56    | 0     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1  Reaction Name                | Total | Fatal |
|---|-------|-------|
| Muscle & tissue disorders                                 |       |       |
| Arthropathies NEC   |       |       |
| Arthritis   | 7     | 0     |
| Arthropathy   | 1     | 0     |
| Bone related signs and symptoms                           | · ·   |       |
| Bone pain   | 4     | 0     |
| Spinal pain   | 1     | 0     |
| Bursal disorders  |       |       |
| Bursitis  | 1     | 0     |
| Cartilage disorders                                       |       |       |
| Costochondritis   | 3     | 0     |
| Connective tissue disorders NEC                           | J     |       |
| Polymyalgia rheumatica                                    | 3     | 0     |
| Joint related disorders NEC                               | J     |       |
| Hypermobility syndrome                                    | 1     | 0     |
| Joint lock  | 1     | 0     |
| Periarthritis   | 3     | 0     |
| Joint related signs and symptoms                          |       | J     |
| Arthralgia  | 84    | 0     |
| Joint stiffness   | 2     | 0     |
| Joint swelling  | 10    | 0     |
| Lupus erythematosus (incl subtypes)                       | 10    | U     |
| Systemic lupus erythematosus                              | 1     | 0     |
| Muscle pains  |       | U     |
| Fibromyalgia  | 2     | 0     |
| Myalgia   | 75    | 0     |
| Muscle related signs and symptoms NEC                     | 7.5   | U     |
| Muscle disorder   | 1     | 0     |
| Muscle fatigue  | 3     | 0     |
| Muscle spasms   | 13    | 0     |
| Muscle tightness  | 2     | 0     |
| Muscle twitching  | 1     | 0     |
| Muscle twitering  Muscle tone abnormalities               | '     | U     |
| Muscle rigidity   | 4     | 0     |
| Muscle rigidity  Muscle weakness conditions               | 7     | U     |
| Muscular weakness   | 14    | 0     |
| Musculoskeletal and connective tissue conditions NEC      | 17    | U     |
| Back disorder   | 1     | 0     |
| Mobility decreased  | 12    | 0     |
| Musculoskeletal stiffness                                 | 13    | 0     |
| Musculoskeletal and connective tissue pain and discomfort | 13    | U     |
| Back pain   | 26    | 0     |
| Limb discomfort   | 11    | 0     |
| Musculoskeletal chest pain                                | 11    |       |
| Musculoskeletal discomfort                                | 1     | 0     |
|   | 2     |       |
| Musculoskeletal pain                                      | 14    | 0     |
| Neck pain   | 109   | 0     |
| Pain in extremity   | 109   | U     |
| Psoriatic arthropathies                                   | ,     | ^     |
| Psoriatic arthropathy                                     | 1     | 0     |
| Rheumatoid arthropathies                                  | _     | ^     |
| Rheumatoid arthritis                                      | 2     | 0     |
| Soft tissue disorders NEC                                 | 4     | ^     |
| Groin pain  | 1     | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name   | Total | Fatal |
|---|-------|-------|
| Muscle & tissue disorders e & tissue disorders cont'd |       |       |
| Spondyloarthropathies                                 |       |       |
| Arthritis reactive                                    | 1     | 0     |
| Tendon disorders                                      |       |       |
| Tendonitis  | 1     | 0     |
| Muscle & tissue disorders SOC TOTAL                   | 433   | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name   | Total | Fatal |
|---|-------|-------|
| Neoplasms   |       |       |
| Breast and nipple neoplasms malignant                                       |       |       |
| Breast cancer   | 1     | 0     |
| Breast cancer female  | 1     | 0     |
| Haematologic neoplasms NEC  |       |       |
| Benign lymph node neoplasm  | 1     | 0     |
| Leukaemias chronic lymphocytic  |       |       |
| Chronic lymphocytic leukaemia   | 1     | 0     |
| Neoplasms malignant site unspecified NEC                                    |       |       |
| Malignant neoplasm progression  | 1     | 0     |
| Neoplasm malignant  | 1     | 0     |
| Respiratory tract and pleural neoplasms malignant cell type unspecified NEC |       |       |
| Throat cancer   | 1     | 0     |
| Skin neoplasms benign   |       |       |
| Skin papilloma  | 1     | 0     |
| Neoplasms SOC TOTAL   | 8     | 0     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name         Total         Fat           Nervous system disorders         4 cute polyneuropathies         6           Guillain-Barre syndrome         6           Autonomic nervous system disorders         1           Orthostatic intolerance         1           Central nervous system haemorrhages and cerebrovascular accidents         1           Basilar artery thrombosis         1           Carotid artery occlusion         1           Cerebrovascular accident         8           Haemorrhage intracranial         1           Cerebrovascular venous and sinus thrombosis         1           Corna states         2           Coma states         2           Coma Coordination and balance disturbances         1           Balance disorder         9           Coordination abnormal         2           Dysstasia         2           Cortical dysfunction NEC         2           Aphasia         2           Disturbances in consciousness NEC         2           Lethargy         26           Loss of consciousness         8           Somnolence         14           Syncope         15           Dyskinesias and movement disorders NEC | 0 0 0 0 0 0 0 0 0 0                            |
|--|--|
| Acute polyneuropathies Guillain-Barre syndrome Autonomic nervous system disorders Orthostatic intolerance Central nervous system haemorrhages and cerebrovascular accidents Basilar artery thrombosis Carotid artery occlusion Cerebrovascular accident Haemorrhage intracranial 1 Cerebrovascular venous and sinus thrombosis Cerebral venous sinus thrombosis Coma states Coma 1 Coordination and balance disturbances Balance disorder Coordination abnormal Dysstasia 2 Cortical dysfunction NEC Aphasia Disturbances in consciousness NEC Lethargy Loss of consciousness Somnolence Syncope Dyskinesias and movement disorders NEC Bradykinesia   | 0 1 0 0 0 0 0 0 0 0                            |
| Guillain-Barre syndrome  Autonomic nervous system disorders Orthostatic intolerance  Central nervous system haemorrhages and cerebrovascular accidents  Basilar artery thrombosis Carotid artery occlusion Cerebrovascular accident Haemorrhage intracranial Cerebrovascular venous and sinus thrombosis Cerebral venous sinus thrombosis Coma states Coma Coma states Coma Coordination and balance disturbances Balance disorder Coordination abnormal Dysstasia Cortical dysfunction NEC Aphasia 2 Disturbances in consciousness NEC Lethargy Loss of consciousness Somnolence Syncope Dyskinesias and movement disorders NEC Bradykinesia  | 0 1 0 0 0 0 0 0 0 0                            |
| Autonomic nervous system disorders Orthostatic intolerance Central nervous system haemorrhages and cerebrovascular accidents Basilar artery thrombosis Carotid artery occlusion Cerebrovascular accident Haemorrhage intracranial Cerebrovascular venous and sinus thrombosis Cerebral venous sinus thrombosis Cerebral venous sinus thrombosis Coma tates Coma Coordination and balance disturbances Balance disorder Coordination abnormal Dysstasia Cortical dysfunction NEC Aphasia Disturbances in consciousness NEC Lethargy Loss of consciousness Somnolence Syncope Dyskinesias and movement disorders NEC Bradykinesia  | 0 1 0 0 0 0 0 0 0 0                            |
| Orthostatic intolerance  Central nervous system haemorrhages and cerebrovascular accidents  Basilar artery thrombosis  Carotid artery occlusion  Cerebrovascular accident  Haemorrhage intracranial  Cerebrovascular venous and sinus thrombosis  Cerebral venous sinus thrombosis  Coma states  Coma  Coordination and balance disturbances  Balance disorder  Coordination abnormal  Dysstasia  Cortical dysfunction NEC  Aphasia  Disturbances in consciousness NEC  Lethargy  Loss of consciousness  Somnolence  Syncope  Dyskinesias and movement disorders NEC  Bradykinesia  1  Lethargy  Loss of Enselysinesia  Bradykinesia  Loss of Consciousness NEC  Bradykinesia  | 1<br>0<br>0<br>0<br>1<br>0<br>0<br>0<br>0      |
| Basilar artery thrombosis       1         Carotid artery occlusion       1         Cerebrovascular accident       8         Haemorrhage intracranial       1         Cerebrovascular venous and sinus thrombosis       1         Cerebral venous sinus thrombosis       1         Coma states       1         Coma       1         Coordination and balance disturbances       9         Balance disorder       9         Coordination abnormal       2         Dysstasia       2         Cortical dysfunction NEC       2         Aphasia       2         Disturbances in consciousness NEC       2         Lethargy       26         Loss of consciousness       8         Somnolence       14         Syncope       15         Dyskinesias and movement disorders NEC       1         Bradykinesia       1  | 1<br>0<br>0<br>0<br>1<br>0<br>0<br>0<br>0<br>0 |
| Basilar artery thrombosis       1         Carotid artery occlusion       1         Cerebrovascular accident       8         Haemorrhage intracranial       1         Cerebrovascular venous and sinus thrombosis       1         Cerebral venous sinus thrombosis       1         Coma states       1         Coma       1         Coordination and balance disturbances       9         Balance disorder       9         Coordination abnormal       2         Dysstasia       2         Cortical dysfunction NEC       2         Aphasia       2         Disturbances in consciousness NEC       2         Lethargy       26         Loss of consciousness       8         Somnolence       14         Syncope       15         Dyskinesias and movement disorders NEC       1         Bradykinesia       1  | 0<br>0<br>0<br>1<br>1<br>0<br>0<br>0<br>0<br>0 |
| Carotid artery occlusion       1         Cerebrovascular accident       8         Haemorrhage intracranial       1         Cerebrovascular venous and sinus thrombosis       1         Cerebral venous sinus thrombosis       1         Coma states       1         Coma       1         Coordination and balance disturbances       9         Balance disorder       9         Coordination abnormal       2         Dysstasia       2         Cortical dysfunction NEC       2         Aphasia       2         Disturbances in consciousness NEC       2         Lethargy       26         Loss of consciousness       8         Somnolence       14         Syncope       15         Dyskinesias and movement disorders NEC       1         Bradykinesia       1  | 0<br>0<br>1<br>1<br>0<br>0<br>0<br>0<br>0      |
| Haemorrhage intracranial  Cerebrovascular venous and sinus thrombosis  Cerebral venous sinus thrombosis  Coma states  Coma  Coordination and balance disturbances  Balance disorder  Coordination abnormal  Dysstasia  Cortical dysfunction NEC  Aphasia  Disturbances in consciousness NEC  Lethargy  Loss of consciousness  Somnolence  Syncope  Dyskinesias and movement disorders NEC  Bradykinesia  1   | 0 1 0 0 0 0 0 0 0                              |
| Cerebrovascular venous and sinus thrombosisCerebral venous sinus thrombosis1Coma states1Coma1Coordination and balance disturbances9Balance disorder9Coordination abnormal2Dysstasia2Cortical dysfunction NEC2Aphasia2Disturbances in consciousness NEC2Lethargy26Loss of consciousness8Somnolence14Syncope15Dyskinesias and movement disorders NECBradykinesia1  | 1 0 0 0 0 0 0 0 0                              |
| Cerebral venous sinus thrombosis       1         Coma states       1         Coma       1         Coordination and balance disturbances       9         Balance disorder       9         Coordination abnormal       2         Dysstasia       2         Cortical dysfunction NEC       2         Aphasia       2         Disturbances in consciousness NEC       2         Lethargy       26         Loss of consciousness       8         Somnolence       14         Syncope       15         Dyskinesias and movement disorders NEC       15         Bradykinesia       1  | 0 0 0 0 0 0 0                                  |
| Coma states         1           Coordination and balance disturbances         9           Balance disorder         9           Coordination abnormal         2           Dysstasia         2           Cortical dysfunction NEC         2           Aphasia         2           Disturbances in consciousness NEC         2           Lethargy         26           Loss of consciousness         8           Somnolence         14           Syncope         15           Dyskinesias and movement disorders NEC         15           Bradykinesia         1  | 0 0 0 0 0 0 0                                  |
| Coma Coordination and balance disturbances Balance disorder Coordination abnormal Dysstasia Cortical dysfunction NEC Aphasia Disturbances in consciousness NEC Lethargy Loss of consciousness Somnolence Syncope Dyskinesias and movement disorders NEC Bradykinesia   | 0 0 0 0  |
| Coordination and balance disturbances9Balance disorder9Coordination abnormal2Dysstasia2Cortical dysfunction NEC2Aphasia2Disturbances in consciousness NEC26Lethargy26Loss of consciousness8Somnolence14Syncope15Dyskinesias and movement disorders NEC1Bradykinesia1   | 0 0 0  |
| Balance disorder       9         Coordination abnormal       2         Dysstasia       2         Cortical dysfunction NEC       2         Aphasia       2         Disturbances in consciousness NEC       2         Lethargy       26         Loss of consciousness       8         Somnolence       14         Syncope       15         Dyskinesias and movement disorders NEC       1         Bradykinesia       1   | 0 0 0 0  |
| Coordination abnormal       2         Dysstasia       2         Cortical dysfunction NEC       2         Aphasia       2         Disturbances in consciousness NEC       2         Lethargy       26         Loss of consciousness       8         Somnolence       14         Syncope       15         Dyskinesias and movement disorders NEC       1         Bradykinesia       1  | 0 0 0  |
| Dysstasia       2         Cortical dysfunction NEC       2         Aphasia       2         Disturbances in consciousness NEC       2         Lethargy       26         Loss of consciousness       8         Somnolence       14         Syncope       15         Dyskinesias and movement disorders NEC       1         Bradykinesia       1  | 0 0 0  |
| Cortical dysfunction NEC Aphasia 2 Disturbances in consciousness NEC Lethargy 26 Loss of consciousness 8 Somnolence 14 Syncope 15 Dyskinesias and movement disorders NEC Bradykinesia 1  | 0  |
| Aphasia 2  Disturbances in consciousness NEC  Lethargy 26  Loss of consciousness 8  Somnolence 14  Syncope 15  Dyskinesias and movement disorders NEC  Bradykinesia 1  | 0  |
| Disturbances in consciousness NECLethargy26Loss of consciousness8Somnolence14Syncope15Dyskinesias and movement disorders NEC1Bradykinesia1   | 0  |
| Lethargy 26 Loss of consciousness 8 Somnolence 14 Syncope 15 Dyskinesias and movement disorders NEC Bradykinesia 1   | 0  |
| Loss of consciousness Somnolence Syncope 15 Dyskinesias and movement disorders NEC Bradykinesia 1  | 0  |
| Somnolence 14 Syncope 15  Dyskinesias and movement disorders NEC Bradykinesia 1  |  |
| Syncope 15  **Dyskinesias and movement disorders NEC**  Bradykinesia 1   | 0  |
| Dyskinesias and movement disorders NEC Bradykinesia 1  |  |
| Bradykinesia 1   | 0  |
|  |  |
| Hypokinesia   1  | 0  |
|  | 0  |
| Movement disorder 1  | 0  |
| Encephalopathies NEC   | _  |
| Autoimmune encephalopathy 1  | 0  |
| Eye movement disorders   | ^  |
| VIth nerve paralysis   | 0  |
| Facial cranial nerve disorders   | _  |
| Bell's palsy 2   | 0  |
|  | U  |
| Facial paresis 1 Headaches NEC   | 0  |
| Cluster headache   | 0  |
|  | 0  |
|  | 0  |
| Sinus headache 2 Tension headache 5  | 0  |
| Increased intracranial pressure disorders  | U  |
| Brain oedema 1   | 0  |
| Memory loss (excl dementia)  | U  |
| Amnesia 6  | 0  |
| Memory impairment 3  | 0  |
| Meningitis NEC   | U  |
| Meningitis noninfective 1  | 0  |
| Mental impairment (excl dementia and memory loss)  | Ū  |
| Cognitive disorder 1   | 0  |
| Disturbance in attention 3   | 0  |
| Mental impairment 1  | 0  |
| Migraine headaches   | J  |

### Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24                           | .1           |       |
|---|--------------|-------|
| Reaction Name                                       | <u>Total</u> | Fatal |
| Nervous system disorders us system disorders cont'd |              |       |
| Migraine  | 35           | O     |
| Retinal migraine                                    | 1            | C     |
| Mononeuropathies                                    |              |       |
| Carpal tunnel syndrome                              | 1            | 0     |
| Multiple sclerosis acute and progressive            |              |       |
| Multiple sclerosis                                  | 2            | 0     |
| Narcolepsy and hypersomnia                          |              |       |
| Hypersomnia   | 1            | 0     |
| Nervous system disorders NEC                        |              |       |
| Nervous system disorder                             | 2            | 0     |
| Neurological signs and symptoms NEC                 |              |       |
| Dizziness   | 92           | 0     |
| Dizziness postural                                  | 7            | 0     |
| Meningism   | 1            | 0     |
| Myoclonus   | 1            | 0     |
| Neurological symptom                                | 1            | 0     |
| Presyncope  | 3            | 0     |
| Unresponsive to stimuli                             | 3            | 0     |
| Olfactory nerve disorders                           |              |       |
| Anosmia   | 1            | 0     |
| Parosmia  | 2            | 0     |
| Paraesthesias and dysaesthesias                     |              |       |
| Burning sensation                                   | 10           | 0     |
| Hypoaesthesia                                       | 28           | 0     |
| Paraesthesia  | 37           | 0     |
| Paralysis and paresis (excl cranial nerve)          |              |       |
| Hemiparesis   | 2            | 0     |
| Hemiplegia  | 1            | 0     |
| Monoplegia  | 1            | 0     |
| Paralysis   | 2            | 0     |
| Parkinson's disease and parkinsonism                |              |       |
| Freezing phenomenon                                 | 1            | 0     |
| Parkinson's disease                                 | 1            | 0     |
| Peripheral neuropathies NEC                         |              |       |
| Neuropathy peripheral                               | 1            | 0     |
| Seizures and seizure disorders NEC                  |              |       |
| Convulsions local                                   | 1            | 0     |
| Epilepsy  | 3            | 0     |
| Psychogenic seizure                                 | 1            | 0     |
| Seizure   | 9            | 0     |
| Seizure like phenomena                              | 1            | 0     |
| Sensory abnormalities NEC                           |              |       |
| Ageusia   | 4            | 0     |
| Dysgeusia   | 7            | 0     |
| Neuralgia   | 7            | 0     |
| Restless legs syndrome                              | 2            | 0     |
| Sensory disturbance                                 | 3            | 0     |
| Sensory loss  | 1            | 0     |
| Taste disorder                                      | 1            | C     |
| Speech and language abnormalities                   |              |       |
| Dysarthria  | 5            | C     |
| Transient cerebrovascular events                    |              |       |
| Transient ischaemic attack                          | 3            | O     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                                       | Total | Fatal |
|---|-------|-------|
| Nervous system disorders us system disorders cont'd |       |       |
| Tremor (excl congenital)                            |       |       |
| Tremor  | 47    | 0     |
| Trigeminal disorders                                |       |       |
| Trigeminal neuralgia                                | 1     | 0     |
| Nervous system disorders SOC TOTAL                  | 726   | 2     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                           | Total | Fatal |
|---|-------|-------|
| Pregnancy conditions                    |       |       |
| Abortions spontaneous                   |       |       |
| Abortion spontaneous                    | 3     | 0     |
| Maternal complications of pregnancy NEC |       |       |
| Preterm premature rupture of membranes  | 1     | 0     |
| Normal pregnancy, labour and delivery   |       |       |
| Pregnancy                               | 1     | 0     |
| Pregnancy conditions SOC TOTAL          | 5     | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                          | Total | Fatal |
|--|-------|-------|
| Product supply and availability issues |       |       |
| Product availability issue             | 1     | 0     |
| null SOC TOTAL                         | 1     | 0     |

### Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1                      |  |              |
|--|--|--------------|
| Reaction Name                                    | <u>  Total                                    </u> | <u>Fatal</u> |
| Psychiatric disorders                            |  |              |
| Abnormal behaviour NEC                           |  |              |
| Abnormal behaviour                               | 1  | 0            |
| Anxiety symptoms                                 |  |              |
| Anxiety  | 9  | 0            |
| Nervousness                                      | 2  | 0            |
| Stress   | 3  | 0            |
| Behaviour and socialisation disturbances         |  |              |
| Personality change                               | 1  | 0            |
| Confusion and disorientation                     |  |              |
| Confusional state                                | 15   | 0            |
| Disorientation                                   | 5  | 0            |
| Deliria  |  |              |
| Delirium   | 1  | 0            |
| Depressive disorders                             |  |              |
| Depression                                       | 2  | 0            |
| Dissociative states                              |  |              |
| Dissociative amnesia                             | 1  | 0            |
| Disturbances in initiating and maintaining sleep |  |              |
| Insomnia   | 13   | 0            |
| Dyssomnias                                       |  |              |
| Poor quality sleep                               | 2  | 0            |
| Emotional and mood disturbances NEC              |  |              |
| Anger  | 1  | 0            |
| Emotional disorder                               | 1  | 0            |
| Irritability                                     | 1  | 0            |
| Mood altered                                     | 1  | 0            |
| Fluctuating mood symptoms                        |  |              |
| Mood swings                                      | 2  | 0            |
| Hallucinations (excl sleep-related)              |  |              |
| Hallucination                                    | 5  | 0            |
| Increased physical activity levels               |  |              |
| Restlessness                                     | 2  | 0            |
| Mental disorders NEC                             |  |              |
| Mental disorder                                  | 2  | 0            |
| Mood alterations with depressive symptoms        |  |              |
| Depressed mood                                   | 4  | 0            |
| Negative thoughts                                | 1  | 0            |
| Panic attacks and disorders                      | _  | _            |
| Panic attack                                     | 3  | 0            |
| Parasomnias                                      |  |              |
| Abnormal dreams                                  | 1  | 0            |
| Nightmare  | 1  | 0            |
| Perception disturbances NEC                      |  |              |
| Autoscopy  | 1  | 0            |
| Psychotic disorder NEC                           |  |              |
| Acute psychosis                                  | 1  | 0            |
| Sleep disorders NEC                              |  |              |
| Sleep disorder                                   | 4  | C            |
| Stress disorders                                 |  |              |
| Post-traumatic stress disorder                   | 1  | C            |
| Suicidal and self-injurious behaviour            |  |              |
| Intentional self-injury                          | 1  | C            |
| Suicidal ideation                                | 1  | 0            |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                                      | Total | Fatal |
|--|-------|-------|
| Psychiatric disorders Psychiatric disorders cont'd |       |       |
| Suicide attempt                                    | 1     | 0     |
| Thinking disturbances                              |       |       |
| Bradyphrenia                                       | 3     | 0     |
| Psychiatric disorders SOC TOTAL                    | 93    | 0     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                             | Total | Fatal |
|---|-------|-------|
| Renal & urinary disorders                 |       |       |
| Bladder and urethral symptoms             |       |       |
| Dysuria                                   | 1     | 0     |
| Urinary incontinence                      | 3     | 0     |
| Urinary retention                         | 1     | 0     |
| Urine flow decreased                      | 1     | 0     |
| Bladder disorders NEC                     |       |       |
| Bladder disorder                          | 1     | 0     |
| Glomerulonephritis and nephrotic syndrome |       |       |
| IgA nephropathy                           | 1     | 0     |
| Nephrotic syndrome                        | 2     | 0     |
| Nephritis NEC                             |       |       |
| Nephritis                                 | 1     | 0     |
| Renal failure and impairment              |       |       |
| Acute kidney injury                       | 2     | 0     |
| Oliguria                                  | 1     | 0     |
| Renal impairment                          | 1     | 0     |
| Renal lithiasis                           |       |       |
| Nephrolithiasis                           | 2     | 0     |
| Renal neoplasms                           |       |       |
| Renal cyst                                | 1     | 0     |
| Renal vascular and ischaemic conditions   |       |       |
| Renal infarct                             | 1     | 0     |
| Renal vein thrombosis                     | 1     | 0     |
| Urinary abnormalities                     |       |       |
| Chromaturia                               | 1     | 0     |
| Haematuria                                | 3     | 0     |
| Proteinuria                               | 1     | 0     |
| Urine odour abnormal                      | 1     | 0     |
| Urinary tract signs and symptoms NEC      |       |       |
| Nocturia                                  | 1     | 0     |
| Renal pain                                | 3     | 0     |
| Renal & urinary disorders SOC TOTAL       | 30    | l o   |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name   | Total | Fatal |
|---|-------|-------|
| Reproductive & breast disorders                       |       |       |
| Breast disorders NEC                                  |       |       |
| Breast mass   | 1     | 0     |
| Breast signs and symptoms                             |       |       |
| Breast pain   | 4     | 0     |
| Breast swelling                                       | 1     | 0     |
| Breast tenderness                                     | 1     | 0     |
| Fallopian tube and ovary infections and inflammations |       |       |
| Noninfective oophoritis                               | 1     | 0     |
| Menopausal effects NEC                                |       |       |
| Menopausal symptoms                                   | 1     | 0     |
| Premature menopause                                   | 3     | 0     |
| Menopausal effects on the genitourinary tract         |       |       |
| Postmenopausal haemorrhage                            | 1     | 0     |
| Menstruation and uterine bleeding NEC                 |       |       |
| Dysmenorrhoea   | 16    | 0     |
| Intermenstrual bleeding                               | 11    | 0     |
| Menstrual disorder                                    | 16    | 0     |
| Menstruation irregular                                | 17    | 0     |
| Premenstrual syndrome                                 | 2     | 0     |
| Menstruation with decreased bleeding                  |       |       |
| Amenorrhoea   | 5     | 0     |
| Hypomenorrhoea  | 4     | 0     |
| Menstruation delayed                                  | 22    | 0     |
| Menstruation with increased bleeding                  |       |       |
| Heavy menstrual bleeding                              | 35    | 0     |
| Polymenorrhoea  | 5     | 0     |
| Ovarian and fallopian tube disorders NEC              |       |       |
| Ovulation disorder                                    | 1     | 0     |
| Ovulation pain  | 1     | 0     |
| Pelvis and broad ligament disorders NEC               |       |       |
| Adnexa uteri pain                                     | 1     | 0     |
| Pelvic haemorrhage                                    | 1     | 0     |
| Prostatic signs, symptoms and disorders NEC           |       |       |
| Prostatic pain  | 1     | 0     |
| Reproductive tract signs and symptoms NEC             |       |       |
| Genital swelling                                      | 1     | 0     |
| Pelvic pain   | 1     | 0     |
| Vulvovaginal disorders NEC                            |       |       |
| Vaginal haemorrhage                                   | 9     | 0     |
| Vulvovaginal disorder                                 | 1     | 0     |
| Vulvovaginal signs and symptoms                       |       |       |
| Vaginal discharge                                     | 1     | 0     |
| Reproductive & breast disorders SOC TOTAL             | 164   |       |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1  Reaction Name                          | Total | Fatal         |
|---|-------|---------------|
| Respiratory disorders   |       |               |
| Breathing abnormalities   |       |               |
| Dyspnoea  | 57    | 1             |
| Dyspnoea exertional   | 1     | 0             |
| Hypopnoea   | 1     | 0             |
| Respiratory arrest  | 1     | 0             |
| Tachypnoea  | 1     | 0             |
| Bronchospasm and obstruction  |       |               |
| Asthma  | 2     | 0             |
| Chronic obstructive pulmonary disease                               | 1     | 0             |
| Wheezing  | 3     | 0             |
| Coughing and associated symptoms                                    |       |               |
| Cough   | 21    | 0             |
| Haemoptysis   | 1     | 0             |
| Productive cough  | 5     | 0             |
| Laryngeal and adjacent sites disorders NEC (excl infections and     |       |               |
| neoplasms)  Reflux laryngitis                                       | 1     | 0             |
| Lower respiratory tract inflammatory and immunologic conditions     | I     | U             |
| Pneumonitis   | 1     | 0             |
| Nasal congestion and inflammations                                  | I     | U             |
| Nasal congestion  | 3     | 0             |
| Nasal disorders NEC   | 3     | U             |
|   | 11    | 0             |
| Epistaxis  Personal sinus disorders (eyel infections and peoplesms) | 11    | 0             |
| Paranasal sinus disorders (excl infections and neoplasms)           | 1     | ^             |
| Sinus congestion  | 1     | 0             |
| Parenchymal lung disorders NEC Interstitial lung disease            | 1     | 0             |
| Pulmonary fibrosis  | 1     | 0             |
| Pharyngeal disorders (excl infections and neoplasms)                |       | U             |
| Pharyngeal swelling   | 1     | 0             |
| Pulmonary oedemas   |       | U             |
| 1   | 1     | 0             |
| Pulmonary congestion  Pulmonary thrombotic and embolic conditions   |       | U             |
| Pulmonary embolism  | 12    | 2             |
| Pulmonary thrombosis  | 1     | 2<br>1        |
| Respiratory tract disorders NEC                                     |       |               |
| Lung disorder   | 1     | 0             |
| Pulmonary mass  | 1     | 0             |
| Upper respiratory tract signs and symptoms                          |       | U             |
| Dysphonia   | 1     | 0             |
| Nasal discomfort  | 1     | 0             |
| Oropharyngeal pain  | 14    | 0             |
| Paranasal sinus discomfort  | 14    | 0             |
| Rhinorrhoea   | 6     |               |
| Sneezing  | 6     | 0             |
| Throat irritation   |       |               |
|   | 2 2   | 0             |
| Yawning Respiratory disorders SOC TOTAL                             | 161   | 0<br><b>4</b> |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1  Reaction Name      | Total            | Fatal |
|---|------------------|-------|
| Skin disorders                                  |                  |       |
| Acnes   |                  |       |
| Acne  | 1                | 0     |
| Alopecias                                       |                  |       |
| Alopecia  | 6                | 0     |
| Angioedemas                                     |                  |       |
| Angioedema                                      | 4                | 0     |
| Apocrine and eccrine gland disorders            |                  |       |
| Cold sweat                                      | 8                | 0     |
| Hyperhidrosis                                   | 39               | 0     |
| Night sweats                                    | 3                | 0     |
| Bullous conditions                              |                  |       |
| Blister   | 3                | 0     |
| Erythema multiforme                             | 1                | 0     |
| Dermal and epidermal conditions NEC             |                  |       |
| Dry skin  | 2<br>1           | 0     |
| Pain of skin                                    | 1                | 0     |
| Papule  | 1                | 0     |
| Scar pain                                       | 1                | 0     |
| Sensitive skin                                  | 2                | 0     |
| Skin burning sensation                          | 2<br>2<br>2<br>1 | 0     |
| Skin discolouration                             | 2                | 0     |
| Skin disorder                                   | 1                | 0     |
| Skin fissures                                   | 1                | 0     |
| Skin indentation                                | 1                | 0     |
| Skin reaction                                   | 1                | 0     |
| Skin swelling                                   | 1                | 0     |
| Skin warm                                       | 1                | 0     |
| Yellow skin                                     | 1                | 0     |
| Dermatitis and eczema                           |                  |       |
| Dermatitis allergic                             | 4                | 0     |
| Eczema  | 3                | 0     |
| Seborrhoeic dermatitis                          | 1                | 0     |
| Skin irritation                                 | 2                | 0     |
| Erythemas                                       |                  |       |
| Erythema  | 29               | 0     |
| Exfoliative conditions                          |                  |       |
| Skin exfoliation                                | 2                | 0     |
| Hyperkeratoses                                  |                  |       |
| _Lichenoid keratosis                            | 1                | 0     |
| Papulosquamous conditions                       |                  | _     |
| Lichen planus                                   | 1                | 0     |
| Photosensitivity and photodermatosis conditions | _                | _     |
| Photosensitivity reaction                       | 1                | 0     |
| Pigmentation changes NEC                        |                  | _     |
| Pigmentation disorder                           | 1                | 0     |
| Pruritus NEC                                    |                  | _     |
| Pruritus  | 36               | 0     |
| Psoriatic conditions                            |                  | -     |
| Psoriasis                                       | 1                | 0     |
| Purpura and related conditions                  |                  |       |
| Petechiae                                       | 2                | 0     |
| Rashes, eruptions and exanthems NEC             |                  | _     |
| Rash  | 63               | 0     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                        | Total | Fatal |
|--------------------------------------|-------|-------|
| Skin disorders Skin disorders cont'd |       |       |
| Rash erythematous                    | 7     | 0     |
| Rash macular                         | 3     | 0     |
| Rash morbilliform                    | 1     | 0     |
| Rash papular                         | 2     | 0     |
| Rash pruritic                        | 15    | 0     |
| Rash vesicular                       | 1     | 0     |
| Scaly conditions                     |       |       |
| Pityriasis                           | 1     | 0     |
| Skin haemorrhages                    |       |       |
| Haemorrhage subcutaneous             | 1     | 0     |
| Skin haemorrhage                     | 1     | 0     |
| Urticarias                           |       |       |
| Cold urticaria                       | 2     | 0     |
| Urticaria                            | 15    | 0     |
| Skin disorders SOC TOTAL             | 279   | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                  | Total | Fatal |
|--------------------------------|-------|-------|
| Social circumstances           |       |       |
| Age related issues             |       |       |
| Menopause                      | 2     | 0     |
| Postmenopause                  | 1     | 0     |
| Disability issues              |       |       |
| Bedridden                      | 1     | 0     |
| Social circumstances SOC TOTAL | 4     | 0     |

# Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| Reaction Name                           | Total | Fatal |
|---|-------|-------|
| Surgical & medical procedures           |       |       |
| Contraceptive methods female            |       |       |
| Contraception                           | 1     | 0     |
| Immunisations                           |       |       |
| COVID-19 immunisation                   | 1     | 0     |
| Immunisation                            | 1     | 0     |
| Joint therapeutic procedures            |       |       |
| Knee operation                          | 1     | 0     |
| Limb therapeutic procedures             |       |       |
| Foot operation                          | 1     | 0     |
| Nail therapeutic procedures             |       |       |
| Nail operation                          | 1     | 0     |
| Obstetric therapeutic procedures        |       |       |
| Caesarean section                       | 1     | 0     |
| Therapeutic procedures NEC              |       |       |
| Bed rest                                | 1     | 0     |
| Hospitalisation                         | 1     | 0     |
| Interchange of vaccine products         | 1     | 0     |
| Surgical & medical procedures SOC TOTAL | 10    | 0     |

## Name: COVID-19 vaccine brand unspecified analysis print Run Date: 02-Dec-2021 Data Lock Date: 01-Dec-2021 18:30:04 MedDRA Version: MedDRA 24.1

| MedDRA Version: MedDRA 24.1  Reaction Name                       | Total  | Fatal  |
|--|--------|--------|
| Vascular disorders   | I Olai | - atai |
| Aneurysms and dissections non-site specific                      |        |        |
| Aneurysm   | 1      | 0      |
| Aortic embolism and thrombosis                                   | '      | ١      |
| Aortic embolism and unformbosis                                  | 2      | 0      |
| Aortic thrombosis  | 1      | 0      |
| Circulatory collapse and shock                                   |        |        |
| Circulatory collapse   | 2      | 0      |
| Shock  | 3      | 0      |
| Haemorrhages NEC   |        | 0      |
| Haematoma  | 1      | 0      |
| Haemorrhage  | 20     | 0      |
|  | 20     | 0      |
| Non-site specific embolism and thrombosis Thrombosis             | 10     | _      |
|  | 10     | 0      |
| Non-site specific vascular disorders NEC                         |        | _      |
| Vascular pain  | 2      | 0      |
| Vascular rupture   | -      | 0      |
| Vein discolouration  | 1      | 0      |
| Peripheral embolism and thrombosis                               | 40     | _      |
| Deep vein thrombosis   | 10     | 0      |
| Jugular vein thrombosis  | 1      | 0      |
| Thrombophlebitis   | 2      | 0      |
| Peripheral vascular disorders NEC                                |        | _      |
| Erythromelalgia  | 1      | 0      |
| Flushing   | 2      | 0      |
| Hot flush  | 6      | 0      |
| Peripheral vasoconstriction, necrosis and vascular insufficiency |        | _      |
| Peripheral coldness  | 2      | 0      |
| Raynaud's phenomenon   | 1      | 0      |
| Phlebitis NEC  |        | _      |
| Phlebitis  | 1      | 0      |
| Site specific vascular disorders NEC                             |        | _      |
| Pallor   | 3      | 0      |
| Varicose veins NEC   |        |        |
| Spider vein  | 1      | 0      |
| Varicose vein  | 1      | 0      |
| Vascular hypertensive disorders NEC                              |        |        |
| Hypertension   | 13     | 0      |
| Vascular hypotensive disorders                                   |        |        |
| Hypotension  | 2      | 0      |
| Vascular disorders SOC TOTAL                                     | 90     |        |
| TOTAL REACTIONS FOR DRUG   | 3970   | 32     |
|  |        |        |
| TOTAL REPORTS  | 1307   |        |
| TOTAL FATAL OUTCOME REPORTS                                      |        | 32     |